

Edgar Filing: HAEMONETICS CORP - Form 8-K

HAEMONETICS CORP  
Form 8-K  
November 01, 2004

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 1, 2004

HAEMONETICS CORPORATION

-----  
(Exact name of registrant as specified in its charter)

Massachusetts

1-10730

04-2882273

-----  
(State or other jurisdiction  
of incorporation)

(Commission File  
Number)

(IRS Employer  
Identification No.)

400 Wood Road Braintree, MA

02184

-----  
(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code

(781) 848-7100

-----  
(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions:

Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange  
Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange  
Act (17 CFR 240.13e-4(c))

=====

Item. 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 1, 2004 Haemonetics Corporation (the "Company") issued a press  
release announcing financial results for the second quarter ended October  
2, 2004. A copy of the release is furnished with this report as exhibit  
99.1.

## Edgar Filing: HAEMONETICS CORP - Form 8-K

The information in this current report on Form 8-K and the exhibit attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

### Item. 9.01 FINANCIAL STATEMENTS AND EXHIBITS

#### (c) Exhibits

99.1: Press Release of Haemonetics Corporation dated November 1, 2004

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(Registrant)

Date: October 31, 2004

By: /s/ Ronald J. Ryan

-----  
Ronald J. Ryan, Vice President and Chief  
Financial Officer

2

### EXHIBIT INDEX

Exhibit No.	Subject Matter
99.1	Press Release of Haemonetics Corporation dated November 1, 2004.

3